2 weeks Xeris Biopharma (XERS) Reports Q4 Loss, Misses Revenue Estimates Zacks

Xeris Biopharma (XERS) delivered earnings and revenue surprises of 57.14% and 0.81%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?